Evolent Announces Second Quarter 2024 Results

Revenue of $647.1 million, an increase of$178.0 million or 37.9%, from the three months ended June 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)$52.0 million resulting in an Adjusted EBITDA margin of 8.0%. Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance. Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024. WASHINGTON, Aug. ...